@TaxiBiotech TaxiBiotech

TaxiBiotech posts on X about stocks, biotech, $crnx, $sny the most. They currently have [-------] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours.

Engagements: [-----] #

Mentions: [--] #

Followers: [-------] #

CreatorRank: [---------] #

Social Influence

Social category influence stocks finance cryptocurrencies countries technology brands exchanges social networks currencies celebrities travel destinations

Social topic influence stocks, biotech, $crnx, $sny #12, nasdaq, $nvo #64, data, $xbi #60, $mreo, in the

Top accounts mentioned or mentioned by @maximusholla @saylor @semlereric @hermeslux @alc2022 @rnaianalyst @agnostoxxx @geneinvesting @monacobiotech @petermantas @logoslp @pawcio2009 @thenighttrader2 @grok @themarketear @zerohedge @goosedata @amaymd @lxngevitylab @yaireinhorn

Top assets mentioned Crinetics Pharmaceuticals, Inc. (CRNX) Synthetify (SNY) Novo-Nordisk (NVO) CRISPR Therapeutics AG (CRSP) Merus N.V. Common Shares (MRUS) Marblex (MBX) Kymera Therapeutics, Inc. (KYMR) Regeneron Pharmaceuticals Inc (REGN) Eli Lilly and Company (LLY) Structure Therapeutics Inc. (GPCR) Pfizer, Inc. (PFE) Sanofi (SNY) Krystal Biotech, Inc. Common Stock (KRYS) Biomea Fusion, Inc. (BMEA) BridgeBio Pharma, Inc. Common Stock (BBIO) Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA) Axsome Therapeutics, Inc (AXSM) Denali Therapeutics Inc. Common Stock (DNLI) Hims & Hers Health, Inc. (HIMS) Sana Biotechnology, Inc. (SANA) Ocular Therapeutix, Inc. (OCUL) Candel Therapeutics, Inc. (CADL) GSK plc (GSK) Terns Pharmaceuticals, Inc. (TERN) C4 Therapeutics, Inc (CCCC) Arvinas, Inc (ARVN) uniQure N.V. (QURE) Lexeo Therapeutics, Inc (LXEO) Viking Therapeutics, Inc (VKTX) Bitcoin (BTC) Amgen, Inc. (AMGN) SpringWorks Therapeutics, Inc. Common Stock (SWTX) Nurix Therapeutics, Inc. (NRIX) Novartis AG (NVS) AbbVie Inc (ABBV) Disc Medicine, Inc. Common Stock (IRON) Zenas BioPharma, Inc. (ZBIO) Valneva SE (VALN) Upstream Bio, Inc. (UPB) Century Therapeutics, Inc. (IPSC) Jazz Pharmaceuticals, Inc. (JAZZ) Maze Therapeutics, Inc. (MAZE) Monte Rosa Therapeutics, Inc. (GLUE) Viking Holdings Ltd (VIK) Hyperliquid (HYPE)

Top Social Posts

Top posts by engagements in the last [--] hours

"$CRSP & $VRTX FDA Approval of CASGEVY for Beta Thalassemia Awesome companies On 8th Dec [----] FDA also approved the same system for Sickle Cell Disease. Let's look at how the market reacts. Will it happen again"
X Link 2024-01-17T10:26Z [--] followers, [---] engagements

"FDA Aprueba CASGEVY ($CRSP & $VRTX) para beta Thalasemia. Compaas increbles. El [--] de diciembre [----] la FDA tambin aprob el mismo sistema para anemia falciforme. Veamos como reaccion el mercado. Se repetir la historia"
X Link 2024-01-17T10:26Z [--] followers, [--] engagements

""It doesn't repeat itself but it often rhymes." No se repite pero suele "rimar""
X Link 2024-01-17T19:11Z [--] followers, [--] engagements

"$CRSP -405% $VRTX -0.85% 17/01/2024"
X Link 2024-01-18T09:53Z [--] followers, [---] engagements

"$VRTX Thrilling news for Cystic Fibrosis New triple combo (vanza) matches TRIKAFTA in lung function (FEV1) & shows outstanding improvement in sweat tests. Especially promising for children: "over 50% potentially experiencing no symptoms".+ only once daily. HOPE #Biotech $XBI 👋"
X Link 2024-02-06T09:25Z [--] followers, [---] engagements

"$VRTX Increble Vertex para los pacientes de FQ. Otra Vez Su nuevo "Vanza" iguala a Kaftrio(R) en volumen espiratorio; y mejora mucho el test del sudor. Especialmente en nios:"Ms del 50% pueden desaparecer los sntomas de la enfermedad". Y una vez al da. ESPERANZA #biotech 👋"
X Link 2024-02-06T09:25Z [--] followers, [--] engagements

"$REGN Can IL-4 & IL-13 blocking conquer all. Now REGN adds Chronic Spontaneous Urticaria in Japan Dupixent. $REGN bloquear IL-4 e IL-13 sirve para todo. Ahora aaden la la aprobacin para urticaria espontnea crnica en Japn. Dupixent"
X Link 2024-02-16T10:48Z [--] followers, [--] engagements

"https://ir.gritstonebio.com/news-releases/news-release-details/gritstone-bio-announces-interim-phase-2-data-granite https://ir.gritstonebio.com/news-releases/news-release-details/gritstone-bio-announces-interim-phase-2-data-granite"
X Link 2024-10-01T10:24Z [--] followers, [--] engagements

"$BIIB Biogen: Designacin de Terapia innovadora de la FDA para su antiCD38 para el rechazo de trasplantes de rin. Inhibe a las NK y los autoanticuerpos Parece seguro en [--] pacientes. Solo [--] paciente en el grupo placebo tuvo prdida del injerto.Necesario ensayo grande a futuro"
X Link 2024-10-10T07:00Z [---] followers, [--] engagements

"$JAZZ y #Pharmamar $PHM Me dejan dudas. BIEN: anuncian datos "estadstic. significativos" para zepzelca(R)+atezo en MANTENIMIENTO #cncer de pulmn. Cautela. Cronologa con ZEPZELCA(R): Se aprueba en USA a condicin de que tenga otro ensayo confirmatorio. El Atlantis. (1/3)"
X Link 2024-10-15T18:35Z [--] followers, [--] engagements

"$JAZZ and #Pharmamar $PHM announcement doubts. GOOD: "statistically significant" data for Zepzelca(R)+Atezo in MAINTENANCE for #lung cancer. Caution. Chronology with ZEPZELCA(R): It was approved in the USA to undergo another confirmatory trial. The Atlantis trial (1/3)"
X Link 2024-10-15T18:38Z [--] followers, [---] engagements

"Analysis of biotechnology companies with dendritic cell-targeted therapies. #vaccineswork #vaccine #cancer #dendritic #mRNA $PDSB $IMMU $CVAC https://youtu.be/DuHU1BiE57ksi=gZoqIyoIqUDu1uEF https://youtu.be/DuHU1BiE57ksi=gZoqIyoIqUDu1uEF"
X Link 2024-10-16T11:12Z [---] followers, [---] engagements

"$AURA Datos tempranos de FASE1 en #Cancer de vejiga no invasivo Frmaco "bel-sar". Y tras 7-12das: ciruga habitual Seguro (10% EA grado1) y efectivo (4 de [--] remisin completa. La activacin lumnica funciona) Me encantan los componentes activados con luz (SIGUE)"
X Link 2024-10-18T08:04Z [---] followers, [--] engagements

"$AURA Light-activated drug. Early Phase [--] data in #NonMuscleInvasiveBladderCancer 1st bel-sar" then surgery after 7-12 days Safe (10% grade [--] AE) & effective (4/5 complete remission light activation works) Promising I love light-activated components"
X Link 2024-10-18T08:11Z [---] followers, [--] engagements

"$CAPR CAPRICOR Stock Public offering (75M$) after good data. (BLA and & long-term data from deramiocel) Financials. CASH: 30M$. Revenues: 4M$. Expenses 1/2 year: 30.7M$ #AsAlwaysBiotech Funding research to combat diseases for more #AsAlwaysBiotech https://www.youtube.com/@taxibiotech https://www.youtube.com/@taxibiotech"
X Link 2024-10-18T08:35Z [---] followers, [---] engagements

"Filed a voluntary petition under chapter [--] of the United States Bankruptcy Code. 😔"
X Link 2024-10-19T05:17Z [---] followers, [--] engagements

"@agnostoxxx @GeneInvesting @monaco_biotech @peter_mantas @Logos_LP @Maximus_Holla It seems they were trying to confirm a suspect in a minimal area or neighbourhood Knowing the DNA sequence to search for: A. B. Specific DNA precipitation C. Specific DNA attached to enzymatic reaction or gold particles https://www.sciencedirect.com/science/article/abs/pii/S0003269721000154 https://www.promega.es/en/products/nucleic-acid-extraction/viral-rna-extraction-viral-dna-extraction/wastewater-viral-rna-dna-extraction/ https://www.sciencedirect.com/science/article/abs/pii/S0003269721000154"
X Link 2024-10-20T03:54Z [---] followers, [---] engagements

"$VERU will attempt to overcome a #GLP1 issue for weight loss WITHOUT LOSING MUSCLE MASS. Phase [--] with enobosarm vs placebo vs semaglutide (WEGOVY). Safety and efficacy. Physical function measured by stair climb test at [--] weeks. Ends in January [----] https://ir.verupharma.com/news-events/press-releases https://ir.verupharma.com/news-events/press-releases"
X Link 2024-10-22T10:15Z [--] followers, [--] engagements

"Following key #PDUFA dates for #NASDAQ biotechs. Example: Jan [--] [----]. $VRTX VERTEX Vanza-triple. Well-tolerated met primary & secondary endpoints. VERTEX giving life & hope to thousands. Since Kaftrio(R) approval"
X Link 2024-10-23T09:20Z [---] followers, [--] engagements

"PDUFA drug approval days November [--] $DERM $FBIO DFD29 Rosacea [--] $MRUS Zenocutuzumab Onco [--] $PTCT Upstaza AADC [--] $AUTL Obe-cel Leukemia [--] $APLT Govorestat Galactosemia $JNJ Nipocalimab FNAIT [--] $BGNE Zanidatamab Onco $BBIO Acoramidis ATTR $JAZZ $ZYME Zanidatamab Onco"
X Link 2024-10-24T10:21Z [--] followers, [----] engagements

"$MRUS Merus Analysis of the characteristics and results of zenocutuzumab (ZENO) for FDA approval on the upcoming PDUFA date. Catalyst for $MRUS stock #PDUFA #stocks #nasdaq #biotech #learning #trading #English #EnglishLanguage https://youtu.be/fCq26C81uXA https://youtu.be/fCq26C81uXA"
X Link 2024-10-27T04:48Z [---] followers, [---] engagements

"$MRUS MERUS anlisis caractersticas y resultados del frmaco Zenocutuzumab (ZENO) que presenta la compaa $MRUS MERUS para su aprobacin por parte de la FDA en la prxima fecha de FDUFA. #FDUFA #stocks #nasdaq #biotec #aprender #trading #espaol https://youtu.be/lfS0L6afbhQ https://youtu.be/lfS0L6afbhQ"
X Link 2024-10-27T04:51Z [---] followers, [---] engagements

"$BIIB Biogen. Positive Phase [--] results for IgA nephropathy a cause of chronic kidney disease. antiCD38 (Felzar) showed reductions in proteinuria and kidney stabilization for 18months. Next up phase3 I wonder about the safety. Could CD38 depletion increase infection risk"
X Link 2024-10-28T07:03Z [---] followers, [---] engagements

"WORST #Biotech #Stocks of the Week on #NASDAQ. English. Explanation and Learning #nasdaq #learning #trading #biotech #memestocks #memestonks #memes #english #englishspeaking $MNRS $TCBP $GRTSQ https://youtu.be/vLL5YgSd6B4 https://youtu.be/vLL5YgSd6B4"
X Link 2024-10-28T09:24Z [---] followers, [---] engagements

"#PDUFA DATES ANALYSIS $Mrus analysis English Spanish $Derm analysis English Spanish https://youtu.be/EvVklNYZ274si=4f7YZzAtlp1cQOWT https://youtu.be/EIrQukaShzwsi=ND3nhaHczYcQtVOu https://youtu.be/lfS0L6afbhQsi=pXKw9NVxwj363CSY https://youtu.be/fCq26C81uXAsi=zWcVlkxpNpiMbM8k https://youtu.be/EvVklNYZ274si=4f7YZzAtlp1cQOWT https://youtu.be/EIrQukaShzwsi=ND3nhaHczYcQtVOu https://youtu.be/lfS0L6afbhQsi=pXKw9NVxwj363CSY https://youtu.be/fCq26C81uXAsi=zWcVlkxpNpiMbM8k"
X Link 2024-10-28T10:11Z [--] followers, [---] engagements

"$MNPR MONOPAR. Announces public offering of common stock. This was mentioned on TaxiBiotechs YouTube channel. $MNPR would need to pay AstraZeneca (ALXN) $4M and needed funding to continue. TaxiBiotechs goal: BE AHEAD of everyone. English video https://youtu.be/b6hwqss5z_I https://youtu.be/b6hwqss5z_I"
X Link 2024-10-29T05:23Z [---] followers, [--] engagements

"$MRUS Merus: Last [--] earnings=-10% within days. and tomorrow is the next one 🔍 Zeno PDUFA date is still a mystery but its coming soon🕒 Full analysis here👉 Could this be a discount opportunity* 👀 *Past performance doesnt guarantee future results https://youtu.be/fCq26C81uXAsi=4ogr2Rq6HNEgRaPp https://youtu.be/fCq26C81uXAsi=4ogr2Rq6HNEgRaPp"
X Link 2024-10-29T18:32Z [---] followers, [--] engagements

"$MRUS Merus: Este ao tras los resultados financieros -10% en pocos das. Maana los prximos 🔍 Fecha PDUFA para Zeno sigue siendo un misterio pero se acerca Anlisis aqu Ser una oportunidad *Rendimiento pasado no garantiza los futuros https://youtu.be/lfS0L6afbhQsi=BCobKlku7QdS2_7n https://youtu.be/lfS0L6afbhQsi=BCobKlku7QdS2_7n"
X Link 2024-10-29T18:39Z [---] followers, [--] engagements

"Best Biotech Stocks of the week 03_11_24 on #Nasdaq. #English. Anlysis and explanation #trading #learning $Glue $ENSC $GLYC #Glue #ENSC #GLYC https://youtu.be/5Nd4okPhONMsi=9b7CLD5OYSy_Geu7 https://youtu.be/5Nd4okPhONMsi=9b7CLD5OYSy_Geu7"
X Link 2024-11-03T08:13Z [--] followers, [---] engagements

"Explanation and Learning from WORST Biotech Stocks of the Week on #NASDAQ. English #nasdaq #learning #trading #biotech #english #englishspeaking $EPIX $ELAB $IPA #EPIX #ELAB #IPA https://youtu.be/wukNa2IUjtk https://youtu.be/wukNa2IUjtk"
X Link 2024-11-04T13:26Z [--] followers, [---] engagements

"$MRUS Finalmente tras resultados: -6% y posterior recuperacin hasta niveles previos (+6%). ✅ Pero la FDA extiende su fecha de aprobacin (o no del medicamento) al [--] de febrero para revisar ms info. https://ir.merus.nl/news-releases/news-release-details/merus-receives-fda-extension-pdufa-zenocutuzumab https://ir.merus.nl/news-releases/news-release-details/merus-receives-fda-extension-pdufa-zenocutuzumab"
X Link 2024-11-06T05:12Z [---] followers, [--] engagements

"$MRUS Finally after results: -6% and subsequent recovery to previous levels (+6%). ✅ However the FDA has extended the approval date (or rejection of the drug) to February [--] to review more information. https://ir.merus.nl/news-releases/news-release-details/merus-receives-fda-extension-pdufa-zenocutuzumab https://ir.merus.nl/news-releases/news-release-details/merus-receives-fda-extension-pdufa-zenocutuzumab"
X Link 2024-11-06T05:13Z [---] followers, [--] engagements

"$MRUS the FDA has extended the approval date (or rejection of the drug) to February [--] to review more information. #PDUFA https://x.com/TaxiBiotech/status/1850399102011326806 https://ir.merus.nl/news-releases/news-release-details/merus-receives-fda-extension-pdufa-zenocutuzumab $MRUS Merus Analysis of the characteristics and results of zenocutuzumab (ZENO) for FDA approval on the upcoming PDUFA date. Catalyst for $MRUS stock #PDUFA #stocks #nasdaq #biotech #learning #trading #English #EnglishLanguage https://t.co/mVeuQ8nCUD https://x.com/TaxiBiotech/status/1850399102011326806"
X Link 2024-11-06T05:19Z [--] followers, [--] engagements

"$MRUS la FDA extiende su fecha de aprobacin (o no del medicamento) al [--] de febrero para revisar ms info. #PDUFA https://x.com/TaxiBiotech/status/1850399827894419724 https://ir.merus.nl/news-releases/news-release-details/merus-receives-fda-extension-pdufa-zenocutuzumab $MRUS MERUS anlisis caractersticas y resultados del frmaco Zenocutuzumab (ZENO) que presenta la compaa $MRUS MERUS para su aprobacin por parte de la FDA en la prxima fecha de FDUFA. https://t.co/WYFZIX0gSe #FDUFA #stocks #nasdaq #biotec #aprender #trading #espaol https://x.com/TaxiBiotech/status/1850399827894419724"
X Link 2024-11-06T05:19Z [---] followers, [--] engagements

"$MRUS the FDA has extended PDUFA goal date to February [--] to review more information. It shows that the source of the information was reliable despite not being available on most websites https://ir.merus.nl/news-releases/news-release-details/merus-receives-fda-extension-pdufa-zenocutuzumab https://ir.merus.nl/news-releases/news-release-details/merus-receives-fda-extension-pdufa-zenocutuzumab"
X Link 2024-11-06T05:22Z [---] followers, [--] engagements

"Analysis of $AUTL. FDA Decision on Autolus Therapeutics' Drug CART CD19 obe-cel. [--] nov. #PDUFA #AUTL In English. https://youtu.be/8TpTVtnzD4k https://youtu.be/8TpTVtnzD4k"
X Link 2024-11-07T11:03Z [--] followers, [---] engagements

"$EPIX +30% in a week nearing its $100M cash balance. Makes sense as I discussed in YT video. Now its future depend on the company's outlook which remains uncertain. It's common to see biotech stocks trading below cash balanceeach case is unique https://youtu.be/wukNa2IUjtksi=zgEhet1jbb3sr0ku https://youtu.be/wukNa2IUjtksi=zgEhet1jbb3sr0ku"
X Link 2024-11-08T09:17Z [--] followers, [--] engagements

"$CTKB Cytek "the first company to detect and isolate particles as small as [--] nm for subsequent analysis". #biotech Science progresses alongside technology https://investors.cytekbio.com/news-releases/news-release-details/cytekr-biosciences-becomes-first-company-add-ability-detect https://investors.cytekbio.com/news-releases/news-release-details/cytekr-biosciences-becomes-first-company-add-ability-detect"
X Link 2024-11-08T09:47Z [--] followers, [--] engagements

"$AUTL ✅ FDA approvedone week ahead of the deadline 💊⚡ https://x.com/TaxiBiotech/status/1854479717518201273 Analysis of $AUTL. FDA Decision on Autolus Therapeutics' Drug CART CD19 obe-cel. [--] nov. #PDUFA #AUTL In English. https://t.co/xiIEYNLrOC https://x.com/TaxiBiotech/status/1854479717518201273 Analysis of $AUTL. FDA Decision on Autolus Therapeutics' Drug CART CD19 obe-cel. [--] nov. #PDUFA #AUTL In English. https://t.co/xiIEYNLrOC"
X Link 2024-11-10T05:40Z [--] followers, [---] engagements

"Best Biotech Stocks of the week 11_11_24 on Nasdaq. Anlysis and explanation. In English #English #trading #learning $CELU $BNOX $ANL #CELU #BNOX #ANL https://youtu.be/Kl-NwQ5NzfM https://youtu.be/Kl-NwQ5NzfM"
X Link 2024-11-11T11:41Z [---] followers, [---] engagements

"@pawcio2009 Feels like [----] all over again. If weve learned anything in crypto its this: Just BTC and go to sleep"
X Link 2024-11-12T05:40Z [---] followers, [--] engagements

"#PDUFA approval days December [--] $IONS OLEZARSEN [--] $KXRX ZYNQUISTA [--] $AZN + Daiichi Dato-DXd [--] Zealand GLEPAGLUTIDE [--] $RYTM IMCIVREE [--] $SNDX REVUMENIB [--] $SLNO DCCR [--] $CKPT + $FBIO Cosibeli [--] $BMY + $HALO Opdivo+ENHANZE [--] $NBIX CRINECERFORT $BGNE TEVIMBRA"
X Link 2024-11-13T06:47Z [--] followers, [---] engagements

"REGENERON + SANOFI. $REN + $SAN (PARIS). FDA accepts Dupixent review for chronic spontaneous urticaria (CSU). Resubmission includes confirmatory Ph3 data (image below). With this data Should CSU patients rely on placebo until approval"
X Link 2024-11-15T06:38Z [--] followers, [---] engagements

"REGENERON + SANOFI. $REN + $SAN (PARIS). La FDA acepta la revisin de Dupixent para la urticaria crnica espontnea (CSU). Se incluyen datos confirmatorios de Fase [--] (imagen abajo). Con estos datos deberan los pacientes con CSU utilizar el placebo hasta la aprobacin"
X Link 2024-11-15T06:40Z [---] followers, [---] engagements

"'I take testosterone replacement appropriate for my age.' - R. Kennedy Jr. the new U.S. Secretary of Health (HHS). 📉Bad news for COVID vaccine companies $MRNA $NVAX $BNTX 🚀Good news for testosterone companies $TEVA $NDOI (OTCQX) $LPCN $HALO https://x.com/realDonaldTrump/status/1857170020427595797 I am thrilled to announce Robert F. Kennedy Jr. as The United States Secretary of Health and Human Services (HHS). For too long Americans have been crushed by the industrial food complex and drug companies who have engaged in deception misinformation and disinformation when it"
X Link 2024-11-15T10:12Z [---] followers, [---] engagements

""'Tomo reemplazo de testosterona apropiado para mi edad' R. Kennedy Jr nuevo Secretario de Salud USA (HHS) 📉Malas noticias para las vacunas de COVID $MRNA $NVAX $BNTX 🚀Buenas noticias para las de testosterona $TEVA $NDOI (OTCQX) $LPCN $HALO https://x.com/realDonaldTrump/status/1857170020427595797 I am thrilled to announce Robert F. Kennedy Jr. as The United States Secretary of Health and Human Services (HHS). For too long Americans have been crushed by the industrial food complex and drug companies who have engaged in deception misinformation and disinformation when it"
X Link 2024-11-15T10:16Z [---] followers, [---] engagements

"Best Biotech STOCKS #NASDAQ. Learnings from +500%. Analysis and explanation. #English #trading #learning $CERO $PULM $ALGS #CERO #PULM #ALGS $VKTX #VKTX https://youtu.be/9Cqc6oBhgUs https://youtu.be/9Cqc6oBhgUs"
X Link 2024-11-17T18:04Z [---] followers, [---] engagements

"@TheNightTrader2 the markets can remain irrational longer than you can remain solvent. In the retrospective analyses I do weekly I notice windows of opportunity where the market seems inefficient by not properly valuing certain stocks. Could this be one of them just time. $AUTL"
X Link 2024-11-18T05:38Z [--] followers, [---] engagements

"$CTKB Cytek Biosciences Named Overall BioTech Company of the Year in [----] BioTech Breakthrough Awards Program -30% YTD 😐"
X Link 2024-11-20T05:20Z [--] followers, [--] engagements

"$CTKB Cytek Biosciences nombrada "Empresa Biotecnolgica del Ao" en el programa de premios BioTech Breakthrough Awards [----]. -30% en el ao 😐meh"
X Link 2024-11-20T05:21Z [--] followers, [--] engagements

"$QLGN Qualigen Therapeutics $5.1Million Private Placement. Insights from the market open: Lessons from low-float stocks🚀vs☠ $QLGN 5.1M$ en ronda privada. Observaciones de la apertura del mercado: Lecciones de acciones con bajo float🚀vs☠ #lowfloat https://www.globenewswire.com/news-release/2024/11/25/2987100/0/en/Univest-Securities-LLC-Announces-Successful-Closing-of-5-1-Million-Private-Placement-for-Qualigen-Therapeutics-Inc-NASDAQ-QLGN.html"
X Link 2024-11-26T06:48Z [---] followers, [--] engagements

"$CRVO Cervomed🚨Orphan Drug Status Alert🚨 Neflamapimod for frontotemporal dementia going to Alzheimer 📊Ph2 Results: Dec Ph3: Early [----] 💰Cash: $46M Loss: $4.8M/Q Does Orphan Drug status boost approval Some ✅32.9% vs [----] (Ph1 to approval). 🤔 #Biotech #OrphanDrug"
X Link 2024-11-28T11:39Z [--] followers, [---] engagements

"Learning from Top 🚀& worst Biotechs of the Week $PSTX $CABA $XCUR $SAVA $APLT $OTLK ROCHE #English Analysis and explanation https://youtu.be/qCQw4xhB7Lo https://youtu.be/qCQw4xhB7Lo"
X Link 2024-12-02T06:02Z [--] followers, [---] engagements

"✅$MRUS Merus.🍾#FDA approved ZENOCUTUZUMAB (BIZENGRI) 🔍Analysis here👇#english #biotech https://youtu.be/fCq26C81uXAsi=LyFqueIzu1eXi3Zu https://youtu.be/fCq26C81uXAsi=LyFqueIzu1eXi3Zu"
X Link 2024-12-06T09:16Z [---] followers, [--] engagements

"Pharma Exposed 💊 Are They Seeking Chronic Treatments +📈 Weekly TOP #Biotech Stocks Analysis: $TARA $SNTI $RENB in #English #Investing #Pharma #Trading #Biotech https://youtu.be/jRC39yU4w9M https://youtu.be/jRC39yU4w9M"
X Link 2024-12-09T11:10Z [--] followers, [---] engagements

"$SLRN ACELYRIN. ❌ Phase 2/3 of Izokibep for uveitis fails Stay tuned: 💰 $562M in cash (enough until 2027) vs. $407M market cap. 🧬 Limited pipeline but resources to survive. 👀 Lesson of the week: How does a stock react after a failed trial with enough cash in reserve to survive Big drop and potential recovery #Biotech #Trading #investing https://investors.acelyrin.com/news-releases/news-release-details/acelyrin-inc-announces-topline-results-phase-2b3-study-izokibep"
X Link 2024-12-11T05:28Z [--] followers, [--] engagements

"🔥 Low Float Stocks Alert $QNRX QUOIN Pharma. 1.2M Float 🌍 Netherton Syndrome: 1/200k births no treatment available. 💊 Phase [--] drug with promising results: ✔ Improvements seen within [--] days. ✔ MIASI index drops from [--] to [--] in [--] weeks. ✔ New application expanded to 80% of the body. 🚨 Challenges: $IMMX trading below $1 on Nasdaq since March at risk of delisting. 💰 Finances: $10M in cash [--] year of runway. 12-week trial ongoing. https://investors.quoinpharma.com/news-releases/news-release-details/quoin-pharmaceuticals-announces-positive-interim-data-two"
X Link 2024-12-20T09:12Z [--] followers, [---] engagements

"👋👋 Bye bye low float Public offering: 15M shares + warrants at $0.45. They'll raise $6.8M for a $3.2M market cap. Still: 🔥🔥 Up 10% since opening now at $0.59. #ThisIsBiotech https://x.com/TaxiBiotech/status/1870034564522852529 https://investors.quoinpharma.com/news-releases/news-release-details/quoin-pharmaceuticals-announces-pricing-68-million-public 🔥 Low Float Stocks Alert $QNRX QUOIN Pharma. 1.2M Float 🌍 Netherton Syndrome: 1/200k births no treatment available. 💊 Phase [--] drug with promising results: ✔ Improvements seen within [--] days. ✔ MIASI index drops from [--] to [--] in [--] weeks. ✔"
X Link 2024-12-20T20:50Z [--] followers, [--] engagements

"#PDUFA approval days January [--] $ATRA TABELECLEUCEL Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease [--] $BIIB + $ESALF LEQEMBI Alzheimer (IV maintenance dosing) [--] $AZN + $DSKYF DATOpotamab DERUXtecan cancer [--] $VRTX SUZETRIGINE Pain [--] $AXSM AXS-07 Migraine Q1 $ICCM PROSENSE cancer ✅ $MESO RYONCIL acute graft-vs-host-disease ✅ $VRTX Vanza Triple Cystic Fibrosis https://www.rttnews.com/corpinfo/fdacalendar.aspxPageNum=4 https://www.rttnews.com/corpinfo/fdacalendar.aspxPageNum=4"
X Link 2024-12-26T11:02Z [---] followers, [---] engagements

"Perfect timing Axsome $AXSM releases PH3 results for Alzheimers. Not covered in todays video but worth keeping an eye on https://youtu.be/1BdIqYU4IYY https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-successful-completion-and-results https://youtu.be/1BdIqYU4IYY https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-successful-completion-and-results"
X Link 2024-12-30T13:17Z [--] followers, [---] engagements

"🧬 Bio companies diving into crypto: @saylor leads the way followed by @SemlerEric $SMLR and $ENLV with a #Bitcoin strategy. $NIVF portfolio: 55% $BTC/Eth+10%Tether+35% alts 👀 Who will tell them: "There is no second best" https://youtu.be/b5-m4V1xyRQsi=MQnRw1EMJLBBR1Wn https://youtu.be/b5-m4V1xyRQsi=MQnRw1EMJLBBR1Wn"
X Link 2025-01-07T21:24Z [--] followers, [---] engagements

"$SANA Sana #Biotechnology the 🏆 of the day: 🔬 A revolutionary breakthrough: reversing #type1diabetes with donor cell transplants without immunosuppression. 🚀 How did they achieve it advantages and challenges Let me explain in this thread🧵 👇"
X Link 2025-01-08T11:52Z [--] followers, [---] engagements

"A Cure for #Diabetes 🩺 Discover the best #Biotech stocks of the week: $HOTH $SANA and $SPRC. 🔬📈 Analysis scientific insights and key takeaways you can't miss. #Biotechnology #Investing #Trading #DiabetesCure https://youtu.be/XCIs3renpPU https://youtu.be/XCIs3renpPU"
X Link 2025-01-13T08:54Z [--] followers, [---] engagements

"$EDIT Editas. Anticipated [----] milestones: [--] in vivo development candidates one in HSCs and one in liver; present further in vivo HSC data; present in vivo data in one liver indication; establish one additional target cell type/tissue; and continue to derive revenue through sublicensing foundational IP Strategic priorities through [----] include: submit at least one IND/CTA; achieve human in vivo proof of concept in HSC editing for the treatment of sickle cell disease and beta thalassemia; and commence late-stage trial of at least one asset Strong financial position with operational runway into"
X Link 2025-01-14T11:11Z [--] followers, [---] engagements

"$EYPT EyePoint Full data for Phase [--] VERONA clinical trial of DURAVYU in DME expected in 1Q [---] Cash runway into [----] beyond topline DURAVYU Phase [--] wet AMD data expected in 2026"
X Link 2025-01-14T11:12Z [--] followers, [---] engagements

"$OCUL Ocular therapeutics. Age-related macular degeneration (wet AMD) trial SOL-1 Ph3 Topline dat in Q4 [----]. FDA feedback in H1 [----] on clinical trial design for AXPAXLI in non-proliferative diabetic retinopathy (NPDR)"
X Link 2025-01-15T08:39Z [---] followers, [---] engagements

"$KYMR Kymera. KT-621 (STAT6) Ph1 data expected in Q2 [----]. Initiate a KT-621 Ph1b in atopic dermatitis (AD) in Q2 [--] with data in Q4 [--]. Novel oral immunology program with a first-in-class development candidate to be disclosed in 1H25"
X Link 2025-01-21T06:49Z [---] followers, [---] engagements

"https://x.com/TaxiBiotech/status/1872236415356129588 #PDUFA approval days January [--] $ATRA TABELECLEUCEL Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease [--] $BIIB + $ESALF LEQEMBI Alzheimer (IV maintenance dosing) [--] $AZN + $DSKYF DATOpotamab DERUXtecan cancer [--] $VRTX SUZETRIGINE Pain [--] $AXSM AXS-07 https://x.com/TaxiBiotech/status/1872236415356129588 #PDUFA approval days January [--] $ATRA TABELECLEUCEL Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease [--] $BIIB + $ESALF LEQEMBI Alzheimer (IV maintenance dosing) [--] $AZN + $DSKYF DATOpotamab"
X Link 2025-01-21T06:49Z [--] followers, [---] engagements

"More info & references https://x.com/TaxiBiotech/status/1879124280480612776 https://x.com/TaxiBiotech/status/1879448309544386799 🧬#Biotech in 2025: Some Key Milestones and Business Updates Ahead 🧵 Lets dive into the [----] updates and outlook for some companies: https://x.com/TaxiBiotech/status/1879124280480612776 https://x.com/TaxiBiotech/status/1879448309544386799 🧬#Biotech in 2025: Some Key Milestones and Business Updates Ahead 🧵 Lets dive into the [----] updates and outlook for some companies:"
X Link 2025-01-21T06:49Z [--] followers, [--] engagements

"🧬Proyecto StarGate: IA para la cura del cncer Analizo la "idea" de Trump + Sam Altman + Larry Ellison para usar IA en vacunas de mRNA. 🎯 Y muestro acciones biotech con IA: $ABSI $ABCL $SDGR $DNA $BTAI $RXRX https://youtu.be/oZUznjsnNL0 https://youtu.be/oZUznjsnNL0"
X Link 2025-01-23T06:15Z [--] followers, [---] engagements

"🧬StarGate Project: AI for curing cancer I analyse the "idea" of Trump Sam Altman and Larry Ellison using AI in mRNA vaccines. 🎯 Plus I showcase biotech stocks with AI: $ABSI $ABCL $SDGR GinkGo $DNA $BTAI $RXRX https://youtu.be/VyWb7zvotEU https://youtu.be/VyWb7zvotEU"
X Link 2025-01-23T06:31Z [--] followers, [---] engagements

"What do $CADL $HOWL and $EYPT have in common 📈🔬 All three are expecting biotech catalysts this quarter with potential impact on their #Nasdaq listed stocks. Discover the key details in the video (in ENGLISH): Candel Eyepoint Werewolf #Biotech https://youtu.be/lk3_XOUWihU https://youtu.be/lk3_XOUWihU"
X Link 2025-01-27T11:32Z [--] followers, [---] engagements

"$AXSM Axome decisive PDUFA date this week. Jan 31st Reviewed in this video 📽 You can vote for your stock movement predictions here. https://x.com/DomVacchiano/status/1883738551608897635 https://youtu.be/1BdIqYU4IYY How will $AXSM stock move on PDUFA or Currently $103/sh Up +22% past [--] months $5B Mkt Cap $300M Cash https://x.com/DomVacchiano/status/1883738551608897635 https://youtu.be/1BdIqYU4IYY How will $AXSM stock move on PDUFA or Currently $103/sh Up +22% past [--] months $5B Mkt Cap $300M Cash"
X Link 2025-01-28T17:40Z [--] followers, [---] engagements

"Stargate vs DeepSeek 📈 Biotech stocks working on AI remain strong: $ABSI $ABCL $DNA $SDGR 📉 Only a small dip (-5-10%). Will they rebound once the real Chinese cost is clear 🤖 Slapping "AI" on press releases hasnt worked lately. $CDT -7% https://youtu.be/VyWb7zvotEU https://youtu.be/VyWb7zvotEU"
X Link 2025-01-29T06:06Z [--] followers, [---] engagements

"Everyone is aware of this right +17.4B of convertible bonds + 4.3B ATM +585M of $STRK at 85$. + doing more ATM"
X Link 2025-02-07T11:15Z [---] followers, [---] engagements

"☢💊 Radioligands in Cancer Treatment Summary of Therapy Principles + Approved Drugs + Top M&As [----] + Related Biotech Stocks 🌟Telix ($TLX) 🌟 Lantheus ($LNTH) Radiopharm ($RADX) Actinium ($ATNM) Cellectar ($CLRB) English https://youtu.be/XBCEW2s50yg https://youtu.be/XBCEW2s50yg"
X Link 2025-02-11T10:55Z [---] followers, [---] engagements

"☢💊 Radioligands in Cancer Treatment Summary of Therapy Principles + Approved Drugs + Top M&As [----] + Related Biotech Stocks 🌟Telix ( $TLX ) 🌟 Lantheus ( $LNTH ) Radiopharm ( $RADX ) Actinium ( $ATNM ) Cellectar ( $CLRB ) English https://youtu.be/XBCEW2s50yg https://youtu.be/XBCEW2s50yg"
X Link 2025-02-11T18:03Z [---] followers, [---] engagements

"🚨 $ANAB AnaptysBio presents Phase [--] results today for Rheumatoid Arthritis with a PD-1 agonist 🔍 Watch their press release patterns: 📉 Unexpectedly in December they announced another Phase 2b trial failure missing endpoints & canceling the study. Stock -38% 📈 Today they announce a webcast to present PD-1 agonist data in arthritis Sign of success (+21% premarket) 🤔 PD-1 for everything Applying broad mechanisms to a specific disease. I prefer local or targeted approaches. #Biotech #Immunotherapy"
X Link 2025-02-12T11:19Z [---] followers, [---] engagements

"Vaxcyte $PCVX VAX-24 Infant Phase [--] Study by the End of 1Q Topline Data from Booster by the End [----]. Previous behavior: Sept. [--]. Conference + Vax-31 data + offering. 🖼Here's the chart. You know how the game works. Will it be priced in this time"
X Link 2025-02-26T11:30Z [---] followers, [---] engagements

"MESOBLAST $MSB $MESO "Ryoncil for treatment of pediatric SR-aGvHD. twice per week for [--] consecutive weeks. The wholesale acquisition cost is US$194000 per intravenous infusion" 1.5M$/treatment Price for a treatment for a highly fatal complication https://x.com/Mesoblast/status/1894877709425127567 Mesoblast Sets Ryoncil Price Based on Economic Value of Treatment With Planned Product Availability This Quarter https://t.co/S7IP34UcpE https://x.com/Mesoblast/status/1894877709425127567 Mesoblast Sets Ryoncil Price Based on Economic Value of Treatment With Planned Product Availability This Quarter"
X Link 2025-02-27T06:05Z [---] followers, [---] engagements

"🚀Do you know how to handle a 300% rocket 💡 Key strategies to secure a SAFETY NET. 📖+ weekly review $ENVB $ONVO $PEPG $RNA Watch now: #Biotech #Investing #trading #StockMarket $XBI (Not financial advice) https://youtu.be/DnKlZ2sAjeQ https://youtu.be/DnKlZ2sAjeQ"
X Link 2025-03-03T11:52Z [---] followers, [---] engagements

"☣Biotech Finance & stock market. Do you know how to handle a 300% rocket 💡 Key strategies to secure a SAFETY NET. 📖+ weekly review $ENVB $ONVO $PEPG $RNA Watch now: #Biotech #Investing #trading #StockMarket $XBI (Not financial advice) https://youtu.be/DnKlZ2sAjeQ https://youtu.be/DnKlZ2sAjeQ"
X Link 2025-03-03T12:13Z [---] followers, [----] engagements

"Annualized Return of Biotech Funds and ETFs 📊Method: MorningStar Funds/ETFs Biotechnology Sort by 3-Year Return Benchmarks: 📈 S&P [---] $SPY: 12.19% 3-Year Annualized Return 🧬 Biotech $XBI: 1.59% 3year/-0.98% 5year total return #Nasdaq"
X Link 2025-03-06T13:28Z [---] followers, [--] engagements

"🔍 Which small-mid cap biotech companies are held by biotechnology funds 🚖 At @taxibiotech We see the greatest potential to apply our SCIENCE and finance expertise in small and mid-cap. Do you like this strategy 🚀 👇List Below: Ascendis Pharma A/S ADR: $ASND Intra-Cellular Therapies Inc: $ITCI Ionis Pharmaceuticals Inc: $IONS Guardant Health Inc: $GH Alkermes PLC: $ALKS Natera Inc: $NTRA Insmed Inc: $INSM Blueprint Medicines Corp: $BPMC Axsome Therapeutics Inc: $AXSM Twist Bioscience Corp: $TWST Vericel Corp: $VCEL Pharma Mar SA: $PHM InnoCare Pharma Ltd: $33C Verona Pharma PLC ADR: $VRNA"
X Link 2025-03-06T18:16Z [---] followers, [---] engagements

"📢 Can Biotechnology FUNDS / ETFs outperform the S&P500 What Do They Invest In I analyze biotech funds and ETFs and also two stocks with short-term catalysts. $AXSM $ASND $SPX $XBI SP500 💡 Funds or direct biotech investment https://youtu.be/d5rhdmIJTuA https://youtu.be/d5rhdmIJTuA"
X Link 2025-03-10T10:41Z [---] followers, [---] engagements

"PDUFA FDA decision days in April [----] [--] $ALDX REPROXALAP Dry eye [--] $EXEL CABOMETYX expanded use neuro onco [--] $AMGN UPLIZNA Immuno G4 [--] $ARGX VYVGART myasthenia/demyelinating neuro [--] $SNY + $REGN DUPIXENT (resub) 12yo Urticaria [--] $BMY OPDIVO + YERVOY Hepatocellular Carcinoma [--] $TLX TLX101-CDx Glioma Image [--] $ABEO Pz-cel (resub) Dystrophic Epidermolysis Bullos $JNJ NIPOCALIMAB Myasthenia gravis $NVAX NVX-Cov2705 Covid Ref: https://www.rttnews.com/corpinfo/fdacalendar.aspxPageNum=3 https://www.rttnews.com/corpinfo/fdacalendar.aspxPageNum=3"
X Link 2025-03-12T06:41Z [---] followers, [---] engagements

"https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-new-long-term-clinical-data-phase-12 https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-new-long-term-clinical-data-phase-12"
X Link 2025-03-17T12:03Z [---] followers, [--] engagements

"🚨💊 Biotech STOCK News Before NASDAQ Opening 📢 TELIX $TLX expanding in Brazil GYRE $GYRE financials + generic Nanobiotix $NBTX JNJ agreement Sana $SANA preliminary data FibroGen $FGEN sells in China Metagenomi $MGX cash runway until [----] BridgeBio $BBIO new CFO Akoya $AKYA continues with acquisition Quanterix $QTRX stays with Akoya Xoma $XOMA long-term growth 📊📉 How will the market react Follow for more #Biotech and #Investing 🔬💵 https://youtu.be/Bnc_6ru-1LU https://youtu.be/Bnc_6ru-1LU https://youtu.be/Bnc_6ru-1LU https://youtu.be/Bnc_6ru-1LU"
X Link 2025-03-18T11:10Z [---] followers, [----] engagements

"🚨💊 Biotech stock News Before NASDAQ Opening 📢 TELIX $TLX expanding in Brazil GYRE $GYRE financials + generic Nanobiotix $NBTX JNJ agreement Sana $SANA preliminary data FibroGen $FGEN sells in China Metagenomi $MGX cash runway until [----] BridgeBio $BBIO new CFO Akoya $AKYA continues with acquisition Quanterix $QTRX stays with Akoya Xoma $XOMA long-term growth 📊📉 How will the market react Follow for more #Biotech and #Investing 🔬💵 https://youtu.be/Bnc_6ru-1LU https://youtu.be/Bnc_6ru-1LU https://youtu.be/Bnc_6ru-1LU https://youtu.be/Bnc_6ru-1LU"
X Link 2025-03-18T11:11Z [---] followers, [----] engagements

"HUTCHMED $HCM FRUSICA-2 Phase II/III trial of Fruquintinib + Sintilimab met its primary endpoint in advanced renal cell carcinoma (China) ✅ Primary endpoint = progression-free survival (PFS) ✅ improvements in ORR & DoR (secondary) 📢 Full results coming at conferences https://www.hutch-med.com/frusica2-china-phase-iii-of-fruquintinib-sintilimab-met-primary-endpoint-in-rcc/ https://www.hutch-med.com/frusica2-china-phase-iii-of-fruquintinib-sintilimab-met-primary-endpoint-in-rcc/"
X Link 2025-03-19T05:54Z [---] followers, [--] engagements

"🧬Latest financial results and [----] catalysts from biotechnology companies 👇 $BOLT $ARTV $SER $ONX $AURA $CNTA $CLNN $MBRX $BOLT Therapeutics BDC-3042 Ph1 trial results = second quarter [----] CASH $70M runaway through [----]. $ARTV ARTIVA. AlloNK Ph1/1b in 1H [----]. Updated clinial data Ph1/2 AlloNK+rituximab in [----]. Cash $1854M runaway through [----]. $SER Serina therapeutics Net loss [----] $111M$. Cash $3.7M $ONX Oncocyte Loss [----] $335M. CASH = $103M+29.1M. $AURA Cash to fund Op. into 2H [----] $CLNN Clene NDA in 2H [----] Cash $122M. Net Loss [----] $394M $CNTA Centessa ORX750 Phase 2a CRYSTAL-1"
X Link 2025-03-25T09:46Z [---] followers, [---] engagements

"🧬 Hot Biotech Catalysts You Cant Miss 👇 💥 News that could move stock prices 🔹 $ME 23andMe Bankruptcy update Genetic data included in sale. Buyers must comply with privacy agreements. 🔹 $CADL Candel Strong Ph2a data in lung cancer (NSCLC) 🩺 mOS: [----] mo vs [--] mo (SoC) 📈 37% long-term survivors ✅ Safe profile 🔹 $ALVO Alvotech Blowout year 💰 Revenue: $492M (+427% YoY) 📉 Net loss: $231.9M 🔹 $SLNO Soleno FDA Approval ✅ VYKAT XR approved for Prader-Willi hyperphagia 🔹 $BCDA BioCardia Financial results 📉Rev: $58K Loss: $7.9M Cash: $2.4M 🔹 $DYAI Dyadic Financial report. Rev: $3.4M Loss:"
X Link 2025-03-27T10:35Z [---] followers, [---] engagements

"$CLDI Calidi Biotherapeutics 👨🔬 First patient in [--] Ph1 trials expected in Q2/Q3 [----] 📉 Net loss: $23.8M 💰 Cash: $9.6M"
X Link 2025-04-02T09:18Z [---] followers, [---] engagements

"$BMEA Biomea 🧬 COVALENT-111 (T2D) 52-week + COVALENT-112 (T1D) data in 2H [----] 💰 Cash: $58.6M 📉 Net loss: $138.4M"
X Link 2025-04-02T09:18Z [---] followers, [--] engagements

"$SWTX Springworks Fin de la historia. Merck $MRK la compra por 47$ por accin. End of story. Merck bought it for $47 per share. https://x.com/TaxiBiotech/status/1881279761554772406t=vbsDCZYFYaYQzS0EdMIECQ&s=19 $SWTX SpringWorks Therapeutics https://t.co/qPnMYzXjOb https://x.com/TaxiBiotech/status/1881279761554772406t=vbsDCZYFYaYQzS0EdMIECQ&s=19 $SWTX SpringWorks Therapeutics https://t.co/qPnMYzXjOb"
X Link 2025-04-28T06:41Z [---] followers, [---] engagements

"8/ $DAWN (Day One Bio) 💊 Ventas OJEMDA +11% QoQ Prescripciones +16% 🧪 Ph3 FIREFLY-2 completo en 1H [----] 💸 Cash: $473M Prdida neta: $36M"
X Link 2025-05-07T06:42Z [---] followers, [---] engagements

"2/ $SNTI (Senti Bio) SENTI-202 for AML: [--] out of [--] patients achieved composite complete remission (cCR) 💸 Cash: $33.8M 📉 Net loss: $14.1M (Q1'25)"
X Link 2025-05-07T06:46Z [---] followers, [--] engagements

"3/ $GNLX (Genelux) 📌 Ph2 trial in NSCLC enrolling steadily ✅ FDA: Ovarian cancer Ph3 may support approval if meaningful PFS shown 💰 Cash: $35.1M ➜ runway into Q326"
X Link 2025-05-07T06:46Z [---] followers, [--] engagements

"8/ $DAWN (Day One Bio) 💊 OJEMDA revenue +11% QoQ Rx +16% 🧪 FIREFLY-2 Ph3 fully enrolled by 1H [----] 💸 Cash: $473M Net loss: $36M"
X Link 2025-05-07T06:46Z [---] followers, [---] engagements

"2/ $SNTI (Senti Bio) SENTI-202 for AML: [--] out of [--] patients achieved composite complete remission (cCR) 💸 Cash: $33.8M 📉 Net loss: $14.1M (Q1'25)"
X Link 2025-05-07T06:50Z [---] followers, [--] engagements

"8/ $DAWN (Day One Bio) 💊 OJEMDA revenue +11% QoQ Rx +16% 🧪 FIREFLY-2 Ph3 fully enrolled by 1H [----] 💸 Cash: $473M Net loss: $36M"
X Link 2025-05-07T06:50Z [---] followers, [---] engagements

"🧬 Q1 Biotech & Pharma Roundup Night Edition 💉 Clinical updates cash runway outlooks and key milestones from $CTMX $EDIT $CLLS $TNXP and more. Lets dive in. 🧵👇"
X Link 2025-05-13T08:08Z [---] followers, [---] engagements

"🔹 $AVIR ( Atea ) Cash: $425.4M Q1 net loss: $34M"
X Link 2025-05-13T08:08Z [---] followers, [---] engagements

"🔹 $MLYS ( Mineralys ) Explore-CKD Phase [--] topline: Q2 [----] $343M cash supports ops into [----] Net loss: $42.2M"
X Link 2025-05-13T08:08Z [---] followers, [--] engagements

"🔹 $BOLT Cash: $58M Runway into mid-2026"
X Link 2025-05-13T08:08Z [---] followers, [--] engagements

"10/ $RANI (Rani Therapeutics) Announced preclinical data demonstrating the bioequivalence of RT-114 a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill capsule to subcutaneous administration. Initiation of Phase [--] clinical trial of RT-114 for the treatment of obesity is expected in mid-2025. Entered into a partnership with ProGen for the co-development and commercialization of RT-114 including a 50/50 cost and revenue share arrangement. Q1 net loss: $12.7 million. Cash and cash equivalents: $15.9 million"
X Link 2025-05-14T10:47Z [---] followers, [--] engagements

"11/ $MDAI (Spectral AI) Plans to submit a De Novo application to the FDA in the first half of [----]. Q1 [----] R&D revenue: $6.7M (up 6% YoY). Cash position: $14.1M as of March [--] [----]. Secured $15M in debt financing and raised $2.7M in equity financing"
X Link 2025-05-14T10:47Z [---] followers, [--] engagements

"19/ $SLS (SELLAS Life Sciences Group Inc.) Anticipates final analysis of the pivotal Phase [--] REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML) in [----]. Phase [--] trial of SLS009 (tambiciclib) in relapsed/refractory AML showed promising results: median overall survival (mOS) of [---] months in AML-MRC patients and [---] months in patients refractory to venetoclax-based regimens surpassing historical benchmarks of [---] months. Preclinical data SLS009's efficacy in TP53-mutated AML and ASXL1-mutated colorectal cancer; further data to be presented at ASCO [----]. Q1 [----] net loss: $5.8"
X Link 2025-05-14T10:48Z [---] followers, [---] engagements

"24/ Spero Therapeutics $SPRO Upcoming Catalysts: - PIVOT-PO Phase [--] Trial: Interim analysis for tebipenem HBr in complicated urinary tract infections (cUTI) expected in Q2 [----]. - SPR720 Program: Oral development program for nontuberculous mycobacterial pulmonary disease (NTM-PD) suspended; full data analysis of [--] patients underway to determine next steps. Financials: Cash Position: $48.9 million as of March [--] [----]. Net Loss: $13.9 million for Q1 [----]. Cash Runway: Existing funds and upcoming GSK milestone payments expected to fund operations into Q2 2026"
X Link 2025-05-14T10:48Z [---] followers, [--] engagements

"25/ Biodesix ( $BDSX ) Revenue Growth: Q1 [----] revenue reached $18.0M marking a 21% increase year-over-year driven by lung diagnostics and development services. Operational Highlights: Lung Diagnostics revenue grew by 18% achieving the 16th consecutive quarter of over 15% growth. Gross margins improved to 79.4%. Net loss reduced by 18% compared to Q1 [----]. Strategic Moves: Reconfigured sales team into a territory-based structure to enhance reach in pulmonology and primary care sectors. Secured an additional $10M from a term loan facility increasing pro forma cash balance to $27.6M. Financial"
X Link 2025-05-14T10:52Z [---] followers, [---] engagements

"2/ Eledon Pharmaceuticals ( $ELDN ) 🧪 Tegoprubart: Phase [--] BESTOW trial in kidney transplant data in Q4 [----] 🧬 Part of the worlds second successful kidney xenotransplantation 💰 Cash: $124.9M 🛣 Runway through end of 2026"
X Link 2025-05-15T06:30Z [---] followers, [--] engagements

"3/ Nkarta (NKTX) 🧪 NKX019: Two trials in autoimmune diseases (Ntrust-1 & Ntrust-2) data in H2 [----] 🔄 Restructuring: 34% workforce reduction to focus on autoimmunity 💰 Cash: $351.9M 📉 Net loss: $32.0M 🛣 Runway into 2029"
X Link 2025-05-15T06:30Z [---] followers, [--] engagements

"11/ Tenax Therapeutics ( $TENX ) 🧪 TNX-103 (oral levosimendan): Phase [--] LEVEL trial for PH-HFpEF ongoing; enrollment of [---] patients expected to complete around year-end [----]. Topline data anticipated mid-2026. Planning to initiate LEVEL-2 a second global Phase [--] study in [----]. 💰 Cash & equivalents: $111.4M 📉 Net loss: $10.4M in Q1 [----]. 🛣 Runway projected through 2027"
X Link 2025-05-15T06:30Z [---] followers, [---] engagements

"12/ Codexis ( $CDXS ) 🧪 ECO Synthesis Platform: Secured first revenue-generating contract for siRNA manufacturing services; delivered initial orders to major pharmaceutical clients. 💰 Q1 [----] revenue: $7.5M 📉 Net loss: $20.7M 💵 Cash & equivalents: $59.8M 🛣 Runway through end of 2026"
X Link 2025-05-15T06:30Z [---] followers, [---] engagements

"PDUFA FDA decision days in JUNE [----] [--] $MRK CLESROVIMAB. Antibody for RSV [--] $MRNA mRNA-1345. RSV vaccine for adults 18-59 [--] $URGN UGN-102. invasive bladder cancer [--] $KALV SEBETRALSTAT. Hereditary angioedema [--] $GILD LENACAPAVIR. twice-yearly HIV prevention [--] $SNY + $REGN DUPIXENT. bullous pemphigoid +18 [--] $GSK SHINGRIX. prefilled syringe Shingrix (shingles) [--] $NUVB TALETRECTINIB. ROS1+ Lung Cancer [--] $MRK KEYTRUDA. perioperative treatment [--] $UNCY OXYLANTHANUM CARB. Hyperphosphatemia [--] $VSTM AVUTOMETINIB. Recurrent KRAS ovarian cancer"
X Link 2025-05-22T05:32Z [---] followers, [---] engagements

"Investing in BIOTECH. What do you think A hard sector that you need to now very well. 🔬 CRISPR: Real Miracles + A deep dive into [--] companies leading the gene editing revolution: $INTL $BEAM $EDIT $SANA $VERV $CRSP $PRME Let me know if you like it https://youtu.be/iqCvAkWoDhg https://youtu.be/iqCvAkWoDhg"
X Link 2025-05-22T10:21Z [---] followers, [----] engagements

"Investing in BIOTECH. What do you think A hard sector that you need to now very well. 🔬 CRISPR: Real Miracles + A deep dive into [--] companies leading the gene editing revolution: $INTL $BEAM $EDIT $SANA $VERV $CRSP $PRME Let me know if you like https://youtu.be/iqCvAkWoDhg https://youtu.be/iqCvAkWoDhg"
X Link 2025-05-22T15:45Z [---] followers, [----] engagements

"$STRO https://x.com/TaxiBiotech/status/1920780642905710833 3/ $STRO ( Sutro ) 🔄 Portfolio review ➜ Prioritizing next-gen ADCs 🤝 Open to partnerships on Luvelta 🧬 IND for STRO-004 (Tissue Factor ADC) planned 2H25 💰 Cash runway into early [----] https://x.com/TaxiBiotech/status/1920780642905710833 3/ $STRO ( Sutro ) 🔄 Portfolio review ➜ Prioritizing next-gen ADCs 🤝 Open to partnerships on Luvelta 🧬 IND for STRO-004 (Tissue Factor ADC) planned 2H25 💰 Cash runway into early 2027"
X Link 2025-05-30T07:17Z [---] followers, [--] engagements

"$CRNX https://x.com/TaxiBiotech/status/1920780669631742041 17/ $CRNX (Crinetics) 💊 Paltusotine NDA ➜ PDUFA date: Sep [--] [----] 📅 R&D Day: June [--] 💰 Huge cash pile: $1.3B ➜ runway into [----] https://x.com/TaxiBiotech/status/1920780669631742041 17/ $CRNX (Crinetics) 💊 Paltusotine NDA ➜ PDUFA date: Sep [--] [----] 📅 R&D Day: June [--] 💰 Huge cash pile: $1.3B ➜ runway into 2029"
X Link 2025-05-30T07:17Z [---] followers, [---] engagements

"🚨 New data from Roche $RO $RHHBY : fenebrutinib (BTK inhibitor) for multiple sclerosis: near-complete suppression of disease activity & disability progression in relapsing MS for up to [--] years. 🔹 Annualised Relapse Rate ARR: [----] 🔹 No new brain lesions 🔹 No disability worsening"
X Link 2025-05-30T07:33Z [---] followers, [---] engagements

"In this case I don't think they're rotating; it's simply a payment method alongside another form of diversification like holding dollars or euros. But they also talk about crypto. It could be stablecoins or any other shitcoin. If any BIO wants to go down this path they need to focus solely on BTC and forget about shitcoins. Is there still a chance for BTC to help science But as MSTR grows time is running out. https://www.youtube.com/watchv=b5-m4V1xyRQ https://www.youtube.com/watchv=b5-m4V1xyRQ"
X Link 2025-06-04T05:00Z [---] followers, [--] engagements

"From Q1 report: catalysts + cash + competition $CRNX $ASMB $RZLT $FBIO https://x.com/TaxiBiotech/status/1928349977299894467 🔬💰 Biotech investors From Q1 updates Ive picked biotech companies with: ✅ Cash runway until [----] ⚡ Major catalysts in [----] 👇Thread with [--] companies Next: Ill rank their success odds & reveal what Im buying. 📩 Subscribe to find out https://t.co/C7Fe43HFr8 https://x.com/TaxiBiotech/status/1928349977299894467 🔬💰 Biotech investors From Q1 updates Ive picked biotech companies with: ✅ Cash runway until [----] ⚡ Major catalysts in [----] 👇Thread with [--] companies Next: Ill"
X Link 2025-06-06T05:42Z [---] followers, [---] engagements

"🚨 2H [----] Biotech Stock Analysis: 💰 Big cash positions + 🧬scientific catalysts ahead 🎯 Focus on: Crinetics $CRNX Capricor $CAPR Asembly $ASMB Rezolute $RZLT And others $CRSP $FBIO $BLTE $ANAB $GPCR $TERN $STRO $Maze 📺 Watch now: #English https://youtu.be/KL4EzdLQbgQ https://youtu.be/KL4EzdLQbgQ"
X Link 2025-06-09T10:01Z [---] followers, [----] engagements

"🚨 2H [----] Biotech Stock Analysis: 💰 Big cash positions + 🧬scientific catalysts ahead 🎯Focus on: Crinetics $CRNX Capricor $CAPR Asembly $ASMB Rezolute $RZLT And others $CRSP $FBIO $BLTE $ANAB $GPCR $TERN $STRO $Maze 📺 HERE: #English https://youtu.be/KL4EzdLQbgQ https://youtu.be/KL4EzdLQbgQ"
X Link 2025-06-09T13:33Z [---] followers, [----] engagements

"$CABA Massive dilution 🔸 50M shares outstanding before 🔸 aprox. 100M new (shares+warrants) announced $CABA dilucin masiva 🔸 50M de acciones antes del anuncio 🔸 +aprox. 100M de nuevas (acciones + warrants) https://x.com/TaxiBiotech/status/1932764023205847517 https://www.cabalettabio.com/investors/news-events/press-releases/detail/132/cabaletta-bio-announces-pricing-of-public-offering-of $CABA Cabaletta safety-efficacy data + STOCK OFFERING at #EULAR2025: CART therapy for autoimmune diseases 💉 [--] of [--] myositis patients achieved clinically meaningful TIS responses 💉All SLE patients without"
X Link 2025-06-12T09:41Z [---] followers, [---] engagements

"$CRNX It was already known👇 https://youtu.be/KL4EzdLQbgQ https://crinetics.com/crinetics-pharmaceuticals-to-host-rd-day-on-june-26-2025/ https://youtu.be/KL4EzdLQbgQ https://crinetics.com/crinetics-pharmaceuticals-to-host-rd-day-on-june-26-2025/"
X Link 2025-06-16T17:25Z [---] followers, [---] engagements

"Another biotech goes crypto. Eyenovia ( $EYEN ) rebrands to Hyperion DeFi $HYPD and buys $50M worth of HYPE tokens. Abandoning science for vibes. Please stop gambling. There is a way with $BTC for biotech https://youtu.be/b5-m4V1xyRQ https://youtu.be/b5-m4V1xyRQ"
X Link 2025-06-18T09:13Z [---] followers, [---] engagements

"+ $CRNX R&D Day on June [--] [----] https://x.com/Biotech2k1/status/1935661480017285195 https://x.com/Biotech2k1/status/1935661480017285195"
X Link 2025-06-19T12:15Z [---] followers, [---] engagements

"@grok @themarketear @zerohedge Hahaha Spain and Italy will conquer the world againthis time with olives as our secret weapon"
X Link 2025-06-19T17:24Z [---] followers, [--] engagements

"DEGRADADORES MOLECULARES como terapia Qu son y qu biotecs lideran esta revolucin $ARVN $KYMR $NRIX $GLUE $CCCC Arvinas + KYMERA + Nurix + Monte Rosa + C4 Ciencia prometedora y movimientos de mercado con potencial multimillonario. 📺👉 https://youtu.be/i5Z69vyXics https://youtu.be/i5Z69vyXics"
X Link 2025-06-24T11:07Z [---] followers, [---] engagements

"💥 Molecular degraders: What if we could destroy disease-causing proteins How they work + top stocks to watch $ARVN $KYMR $NRIX $CCCC $GLUE Arvinas Kymera Nurix C4 MonteRosa 📺 #biotech #investing #healthtech https://youtu.be/mbLqdIoAbGU https://youtu.be/mbLqdIoAbGU"
X Link 2025-06-24T11:22Z [---] followers, [---] engagements

"💥 Molecular degraders: What if we could destroy disease-causing proteins How they work + top stocks to watch $ARVN $KYMR $NRIX $CCCC $GLUE Arvinas Kymera Nurix C4 MonteRosa 📺 #biotech #investing #Health http://youtu.be/mbLqdIoAbGU http://youtu.be/mbLqdIoAbGU"
X Link 2025-06-24T11:50Z [---] followers, [---] engagements

"💥 Molecular degraders: What if we could destroy disease-causing proteins How they work + top stocks to watch $ARVN $KYMR $NRIX $CCCC $GLUE Arvinas Kymera Nurix C4 MonteRosa 📺 #biotech #investing #HealthForAll http://youtu.be/mbLqdIoAbGU http://youtu.be/mbLqdIoAbGU"
X Link 2025-06-24T11:53Z [---] followers, [----] engagements

"🧬 Cidara $CDTX Clinical success + aggressive dilution = classic biotech [--] Positive Phase 2b results for CD388 (non-vaccine flu prevention) % flu protection vs placebo over [--] weeks: 🟢 450mg 76% 🟡 300mg 61% 🟠 150mg 58% [--] Public offering:8M shares at $0.44 (+1.2M option) Only 13M shares outstanding before. Big dilution. Will the data hold it up"
X Link 2025-06-25T05:42Z [---] followers, [---] engagements

"@GooseData Or vs NIVEA Cream for skin treatments"
X Link 2025-06-26T14:57Z [---] followers, [---] engagements

"🧪 Yesterday was Crinetics $CRNX #RDInvestorDay. They presented preclinical programs and candidates either in phase 1/2 or about to submit new INDs. Lets walk through what they shared. 👇 Thread:"
X Link 2025-06-27T09:54Z [---] followers, [---] engagements

"Thanks for the explanation 🙌 But I still wonder: wouldnt using outstanding shares reflect the immediate impact on the stock price In your view why should we include fully diluted shares for a short-term effect Moreover as FD often includes discounted or employee shares which are usually exercised and sold. Always open to learn and improve"
X Link 2025-06-28T08:17Z [---] followers, [--] engagements

"Thank you man. +Reading their stock structure makes total sense now. As of March [--] [----] we had [--------] shares of common stock outstanding [------] shares of Series A Convertible Voting Preferred Stock outstanding which are convertible into [--------] shares of common stock [------] shares of Series XConvertible Preferred Stock outstanding which are convertible into [------] shares of common stock warrants to purchase up to [---] shares of our common stock outstanding pre-funded warrants to purchase up to [-------] shares of our common stock outstanding and outstanding stock options and restricted stock"
X Link 2025-06-28T16:51Z [---] followers, [--] engagements

"@A_May_MD WoW excellent analysis🙌 Useful note on ETF rebalancing. I wasnt sure if it was done or this week. Stock trades same as when phase [--] failed note that now with $300M less cash. Current datas good outlook strong I also did a modest analysis $NKTR https://youtu.be/3wke2frlPFI https://youtu.be/3wke2frlPFI"
X Link 2025-06-29T22:33Z [---] followers, [----] engagements

"Eyenovia $EYEN EYEN didnt run on clinical data. They jumped +400% by pivoting to crypto $50M treasury into a DeFi coin & a new name. Please biotechnology dont fall into temptation. Save science. Theres no second best. https://www.youtube.com/watchv=3wke2frlPFI https://www.youtube.com/watchv=3wke2frlPFI"
X Link 2025-06-30T08:40Z [---] followers, [---] engagements

"Nektar Therapeutics $NKTR 💰 Public Offering: $100M @ $23.50/sh (42M shares + 638k option) 📊 Shares Outstanding: 12.41M (basic) / Fully diluted 190M 💵 Cash on Hand (Q125): $220M 📉 Net Loss (Q125): $50.9M https://ir.nektar.com/static-files/9ef5aef7-3721-4968-b18c-067e1b46e347 https://ir.nektar.com/news-releases/news-release-details/nektar-therapeutics-announces-pricing-100-million-public https://ir.nektar.com/static-files/9ef5aef7-3721-4968-b18c-067e1b46e347 https://ir.nektar.com/news-releases/news-release-details/nektar-therapeutics-announces-pricing-100-million-public"
X Link 2025-07-01T11:48Z [---] followers, [---] engagements

"I-Mab $IMAB 🧬 Ph1b dose escalation: givastomig (Claudin18.2 4-1BB bispecific) + nivolumab + mFOLFOX6 in 1stLine gastric cancer ✅ ORR: 72% (13/18); 83% (10/12) at expansion dose 🧬 Responses seen even with low PD-L1/CLDN18.2 broader reach 🩺 Mostly Gr12 TRAEs. [--] pt (5.6%) Gr3 transaminase 📍 ESMO GI [----] (Tue 8th) #Biotech #IO #Bispecifics #ESMOGI"
X Link 2025-07-02T17:05Z [---] followers, [---] engagements

"https://www.i-mabbiopharma.com/news-releases/news-release-details/i-mab-presents-positive-givastomig-phase-1b-dose-escalation-data https://www.i-mabbiopharma.com/news-releases/news-release-details/i-mab-presents-positive-givastomig-phase-1b-dose-escalation-data"
X Link 2025-07-02T17:07Z [---] followers, [--] engagements

"Novartis $NVS SWX: $NOVN ❌ Ph3 GCAptAIN (Cosentyx IL-17A inhibitor) in giant cell arteritis (GCA) did not meet the primary endpoint (sustained remission at Week 52) vs placebo ✅ Safety consistent with known profile 🔍 Full data will guide next steps #Biotech #Immunology https://www.globenewswire.com/news-release/2025/07/03/3109648/0/en/Novartis-provides-update-on-Phase-III-GCAptAIN-study-of-Cosentyx-in-giant-cell-arteritis-GCA.html https://www.globenewswire.com/news-release/2025/07/03/3109648/0/en/Novartis-provides-update-on-Phase-III-GCAptAIN-study-of-Cosentyx-in-giant-cell-arteritis-GCA.html"
X Link 2025-07-03T06:14Z [---] followers, [---] engagements

"$COGT COGENT upsized to raise $200M via 22.2M shares @ $9 (+3.3M option) 💰 Cash as of Q1: $245.7M runway into late2026; Net loss Q1: $72M 📊 Shares outstanding: 113.9M 🏢Market cap $1.1B"
X Link 2025-07-09T06:42Z [---] followers, [---] engagements

"💉💸 Weight loss drugs: Caution How do they work Risks benefits worth it Open debate. 👉 + Obesity business: Lilly $LLY and Novo $NVO lead the market. Are rivals too late Viking $VKTX $AMGN $PFE $REGN $ABBV $CRNX $GPCR 🚕 Watch on @TaxiBiotech https://youtu.be/n-X0n7IPNzg https://youtu.be/n-X0n7IPNzg"
X Link 2025-07-12T18:08Z [---] followers, [---] engagements

"💉💸 Weight loss drugs: Caution How do they work Risks benefits worth it Open debate 👉 + Obesity STOCKS: Lilly $LLY and Novo $NVO lead the market. Are rivals too late Viking $VKTX $AMGN $PFE $REGN $ABBV $CRNX $GPCR 🚕 Watch on @TaxiBiotech https://youtu.be/n-X0n7IPNzg https://youtu.be/n-X0n7IPNzg"
X Link 2025-07-12T18:10Z [---] followers, [---] engagements

"💉💸 Weight loss drugs: Caution How do they work Risks benefits worth it Open debate 👉 + Obesity STOCKS: Lilly $LLY and Novo $NVO lead the market. Are rivals too late Viking $VKTX $AMGN $PFE $REGN $ABBV $CRNX $GPCR $MTSR 🚕 Watch on @TaxiBiotech https://youtu.be/n-X0n7IPNzg https://youtu.be/n-X0n7IPNzg"
X Link 2025-07-12T18:41Z [---] followers, [---] engagements

"💉💸 Weight loss drugs: Caution How do they work Risks benefits worth it Open debate. 👉 +Obesity business: Lilly $LLY / Novo $NVO lead the market. Are rivals too late Viking $VKTX $AMGN $PFE $REGN $ABBV $CRNX $GPCR $MTSR 🚕 Watch on @TaxiBiotech https://youtu.be/n-X0n7IPNzg https://youtu.be/n-X0n7IPNzg"
X Link 2025-07-12T18:42Z [---] followers, [---] engagements

"💉💸 Weight loss drugs: Caution How do they work Risks benefits worth it Open debate. 👉 +Obesity business: Lilly $LLY / Novo $NVO lead the market. Are rivals too late Viking $VKTX $AMGN $PFE $REGN $ABBV $CRNX $GPCR $MTSR 🚕@TaxiBiotech https://youtu.be/n-X0n7IPNzg https://youtu.be/n-X0n7IPNzg"
X Link 2025-07-14T05:51Z [---] followers, [----] engagements

"@LxngevityLab Effort diet Meh. Nowadays people look for effortless solutions like Ozempic. Society lies in ruins. Covered in muy vdeo. Good points at this post from @LxngevityLab . For your health: effort+long term. https://youtu.be/n-X0n7IPNzg https://youtu.be/n-X0n7IPNzg"
X Link 2025-07-14T07:01Z [---] followers, [---] engagements

"😅 Yes I missed it. Yes it was right there. 800% The clues for a +800% run in biotech stocks were hidden in the press release and we overlooked them. Today Im breaking it down so it doesnt happen to us again 👉 $INKT $PROK $ARTL https://youtu.be/O4tI-sX4wHk https://youtu.be/O4tI-sX4wHk"
X Link 2025-07-15T08:29Z [---] followers, [---] engagements

"😅 Yes I missed it. Yes it was right there. 800% The clues for a +800% run in biotech stocks were hidden in the press releaseand we overlooked them. Today Im breaking it down so it doesnt happen to us again 👉 $INKT $PROK $ARTL https://youtu.be/O4tI-sX4wHk https://youtu.be/O4tI-sX4wHk"
X Link 2025-07-15T08:38Z [---] followers, [---] engagements

"https://www.globenewswire.com/news-release/2025/07/15/3115481/0/en/Hengrui-Pharma-and-Kailera-Therapeutics-Report-Positive-Topline-Data-from-Phase-3-Obesity-Trial-in-China-of-Dual-GLP-1-GIP-Receptor-Agonist-HRS9531.html https://www.globenewswire.com/news-release/2025/07/15/3115546/0/en/PolyPid-Unveils-a-Long-Acting-GLP-1-Receptor-Agonists-Delivery-Platform-Targeting-the-Diabetes-and-Weight-Loss-Market.html"
X Link 2025-07-15T15:17Z [---] followers, [--] engagements

"@Maximus_Holla $ETHA Does it include the staking rewards"
X Link 2025-07-15T15:54Z [---] followers, [--] engagements

"$SNY Sanofi SAR446597 gets Fast Track in the US One-time intravitreal gene therapy that blocks two complement pathways to tackle geographic atrophy an advanced form of dry AMD that can cause permanent vision loss 👁 #Ophthalmology #GeneTherapy https://www.globenewswire.com/news-release/2025/07/16/3116124/0/en/Press-Release-Sanofi-s-SAR446597-earns-fast-track-designation-in-the-US-for-geographic-atrophy-due-to-age-related-macular-degeneration.html"
X Link 2025-07-16T06:01Z [---] followers, [---] engagements

"🚀 Takeoff phase: AI is accelerating the drug discovery stage from the usual [----] years to just [--] years at a fraction of the cost. The clinical trials pipeline cant keep up with the pace of new molecules being discovered"
X Link 2025-07-16T09:31Z [---] followers, [--] engagements

"🧠 FDA & NIH already in the game: The FDA released draft guidelines for using AI in regulatory decision-making. The FDA also launched its own LLM Elsa to help speed up scientific evaluations. The NIH developed TrialGPT6 to match patients to relevant clinical trials"
X Link 2025-07-16T09:31Z [---] followers, [--] engagements

"Some tools: ConcertAI: tweaks inclusion/exclusion criteria BioPhy: simulates trial outcomes Keiji AI: tackles trial design and data analysis Trial Pathfinder: optimizes eligibility to expand patient pools"
X Link 2025-07-16T09:31Z [---] followers, [--] engagements

"❓ Have you used any of these tools Or the FDAs LLM 🤔 Could AI in clinical trials create bias to favor positive outcomes 💭 Will Phase [--] trials (unbiased real-world) become the new Phase [--] "adulterated" by AI #ClinicalTrials #AI #Biotech"
X Link 2025-07-16T09:31Z [---] followers, [--] engagements

"Novartis $NVS $NOVN Q2 2025: Solid growth Net sales +12%; core operating income +20% with margins expanding to 42.2%. Free cash flow +37% to $6.3B. Kisqali (+64%) Scemblix (+79%) Leqvio (+61%) Kesimpta (+33%) Pluvicto (+30%). 🏆 Key updates: Positive Phase [--] readout for Pluvicto in prostate cancer. Accelerated FDA path for Vanrafia (IgAN) OAV101 (SMA) votoplam (Huntingtons) remibrutinib (food allergy). Share repurchase authorization up to $10B."
X Link 2025-07-17T06:32Z [---] followers, [---] engagements

"Thanks for share. Id like to do some research on this topic. Which molecules is the foundation investing in and which ones still need more funding. Thanks to Vertex and their "kaftors" things have improved. The real challenge in CF is delivery. Gene and RNA-based therapies tested so far have been a major disappointment. Hopefully $PRME can change the story. Homework for this week"
X Link 2025-07-17T14:53Z [---] followers, [---] engagements

"$MESO Mesoblasts Ryoncil (remestemcel-L) commercial launch recap: First & only FDA-approved MSC therapy for pediatric steroid-refractory acute graft-versus-host disease $13.2M in Q2 gross sales (Mar 28Jun 30) $1.6M in royalties from TEMCELL sales in Japan Now covered by Medicare/Medicaid 7-year orphan drug exclusivity + 12-year BLA protection [--] US transplant centers onboarded targeting [--] 🏥 #Biotech #CellTherapy"
X Link 2025-07-18T05:28Z [---] followers, [---] engagements

"🚨📅 July 19: $LXRX Lexicon to present a poster at ASPN [----] on pilavapadin (LX9211) for diabetic neuropathic pain 🧠 ⚠ Last time they presented LX9211 data the stock dropped over 60% due to lack of statistical significance. 📈 It later rebounded after the $NVO deal 🔍 Poster title: Listening to Patients with Diabetic Peripheral Neuropathic Pain: Insights from a Patient Survey to Inform Advanced Clinical Development of Pilavapadin 📌 With that title. I THINK no new clinical data is coming. Just a patient survey to guide future development More qualitative than clinical Stock down 5% today"
X Link 2025-07-18T17:12Z [---] followers, [----] engagements

"#PDUFA #FDA approval days for September: [--] $AXGN AVANCE NERVE GRAFT. Surgical repair. [--] $AGIO PYRUKYND. Anemia for PK deficiency in a/b-thalassemia. [--] $BCRX ORLADEYO. Hereditary angioedema +2yo. [--] $SRKK APITEGROMAB. Spinal muscular atrophy. [--] $IONS $BIIB SPINRAZA. Higher dose for spinal muscular atrophy. [--] $CRNX PALTUSOTINE. Acromegaly. [--] $RPRX AFICAMTEN. Obstructive hypertrophic cardiomyopathy. [--] $SNY TOLEBRUTINIB. Multiple sclerosis. [--] $FBIO CUTX-101. Menkes disease. Late Sept $OMER NARSOPLIMAB. Transplant-associated thrombotic microangiopathy. source:"
X Link 2025-07-21T10:16Z [---] followers, [---] engagements

"ProMis Neurosciences $PMN 🚨 FDA grants Fast Track to PMN310 for #Alzheimer🧠 PMN310 Targets only toxic soluble amyloid-beta sparing normal A and plaques. Fewer side effects more precision. #biotech #Neuroscience https://www.globenewswire.com/news-release/2025/07/21/3118690/0/en/ProMIS-Neurosciences-Granted-Fast-Track-Designation-by-U-S-FDA-for-PMN310-in-the-Treatment-of-Alzheimer-s-Disease.html https://www.globenewswire.com/news-release/2025/07/21/3118690/0/en/ProMIS-Neurosciences-Granted-Fast-Track-Designation-by-U-S-FDA-for-PMN310-in-the-Treatment-of-Alzheimer-s-Disease.html"
X Link 2025-07-21T17:10Z [---] followers, [---] engagements

"🚨 Another NASDAQ BIO chasing BTC BITCOIN Desperate moves are spreading across this sector. What do you think Profusa ( $PFSA ) secures a $100M equity line with Ascent to launch a Bitcoin treasury strategy 🪙 ✅ Theyll issue shares maintain a $5M cash buffer and deploy the rest to buy Bitcoin; which could later be used to repay debt if needed https://www.globenewswire.com/news-release/2025/07/21/3118653/0/en/Profusa-Announces-100-Million-Equity-Line-of-Credit-to-Initiate-Bitcoin-Treasury-Strategy.html"
X Link 2025-07-21T17:21Z [---] followers, [---] engagements

"🚨 Biotech for Sale Crypto projects are pouring millions into struggling biotech firms. $DOGE $LTC $BNB $HYPE + biotech = 🤯 Smart funding model or just marketing hype Is science at risk 🧬 📊 I break it down with [--] final models. https://youtu.be/BLejexow-Yc https://youtu.be/BLejexow-Yc"
X Link 2025-07-24T09:11Z [---] followers, [---] engagements

"🧵 1/ Crypto attack on BIOTECH Several Nasdaq-listed biotech companies are now holding altcoins like $DOGE $LTC $BNB and $HYPE in their treasuries. and $BTC Desperate move or smart strategy Lets break it down case by case. 🎥 Full video at the end. 👇"
X Link 2025-07-25T13:29Z [---] followers, [---] engagements

"8/ What's really going on Three crypto treasury models in biotech: [--] Bitcoin $BTC as passive reserve (e.g. Enlivex) [--] MicroStrategy-style $MSTR accumulation [--] Altcoins using biotech firms for visibility Only one seems science-friendly 👀"
X Link 2025-07-25T13:29Z [---] followers, [---] engagements

"7/ Novo Nordisk $NVO Q2 ventas: +18% ⚠ Rebaja gua 2025: Ventas: 814% (vs 1321%) EBIT: 1016% (vs 1624%) 📉 Menor demanda Wegovy/Ozempic en EE.UU"
X Link 2025-07-30T08:59Z [---] followers, [---] engagements

"6/ uniQure $QURE Q2 revenue: $5.3M (52%) Q2 net loss: $37.7M Cash: $377M runway into H2 [----] 🧬 AMT-130 granted FDA Breakthrough Designation 📄 BLA submission planned Q1 2026"
X Link 2025-07-30T09:02Z [---] followers, [---] engagements

"7/ Novo Nordisk $NVO Q2 sales: +18% ⚠ [----] guidance revised: Sales: 814% (was 1321%) EBIT: 1016% (was 1624%) 📉 Due to softer Wegovy/Ozempic demand in the US"
X Link 2025-07-30T09:02Z [---] followers, [---] engagements

"10/ Kiniksa $KNSA Q2 revenue: $156.8M (+52%) Q2 OpEx: $136.6M Cash: $307.8M [----] active prescribers 🔬 Phase 2/3 trial for KPL387 (pericarditis) underway 🗓 Data expected in 2026"
X Link 2025-07-30T09:02Z [---] followers, [---] engagements

"🧠💊 NewAmsterdam $NAMS isnt developing an Alzheimers drug but Obicetrapib reduced the Alzheimers biomarker ptau217 (20.5%) in APOE4/E4 carriers after [--] months. ✅Its safety vs placebo was already well known. Theres still a long way to go. This could become a post-approval (or not) angle for Obicetrapib as a cholesterol drug. They now need to understand whether tau is being cleared or just shifted and how this impacts cognition. But in Alzheimers any molecular progress is good news. #Alzheimer #Biotech #AAIC25 https://x.com/TaxiBiotech/status/1858762585610317940"
X Link 2025-07-31T05:52Z [---] followers, [---] engagements

"🚕🧬 Time for another round of Q2/H1 [----] Biotech earnings Revenue losses cash and clinical/commercial progress. Here's the rundown 👇"
X Link 2025-07-31T09:51Z [---] followers, [---] engagements

"🧬Biotech watchlist. 1year Cash-backed catalysts from yesterdays financials. 🧵 NASDAQ-only snapshots: Cash P&L Runway Next. Lets go 👇 📺 Ill cover the science on YouTubesubscribe for the deep dive. 🔔"
X Link 2025-08-15T09:26Z [---] followers, [---] engagements

"VYNE Therapeutics $VYNE Cash & securities: $39.6M Net loss (Q2): $5.8M Runway: 1H27 Next: seeking a partner for its topical BET inhibitor repibresib. VYN202: In June [----] the FDA lifted the clinical hold for two doses of VYN202 for female subjects. Further the FDA has indicated that sufficient data from a 12-week non-clinical toxicology study of VYN202 in dogs would be required in order to resume studies in male clinical subjects"
X Link 2025-08-15T09:26Z [---] followers, [---] engagements

"Larimar Therapeutics $LRMR Cash: $138.5M +$65.1M offering Net loss (Q2): $26.2M Runway: Q426 Next: Sep 25: [--] mg open-label + adolescent PK data; Q226: BLA filing (nomlabofusp Friedreichs ataxia)"
X Link 2025-08-15T09:26Z [---] followers, [---] engagements

"🔄OK my Last update on NASDAQ Biotech Watchlist: cash-backed catalysts with 1-yr runway and H225Q126 milestones. Based on August financials & business highlights. Format: Cash P&L Runway Next Milestones 🧵🧬👇"
X Link 2025-08-19T08:51Z [---] followers, [---] engagements

"Mereo BioPharma $MREO Cash: $56.1M Net Loss Q2: $14.6M Runway: [----] Next: YE25 setrusumab DATA Ph3 ORBIT/COSMIC in osteogenesis imperfecta"
X Link 2025-08-19T08:51Z [---] followers, [---] engagements

"Maze Therapeutics $MAZE Cash: $264.5M Net Loss Q2: $33.7M Runway: H227 Next: Q325 MZE782 Ph1 biomarker/Proof of Mechanism for Phenylketonuria (PKU) and Chronic Kidney Disease (CKD); Q126initial data for MZE829 Ph2 PoC APOL1-Mediated Kidney Disease"
X Link 2025-08-19T08:51Z [---] followers, [---] engagements

"CytomX $CTMX Cash: $158.1M Net Loss Q2: $0.15M Runway: Q227 Next: Q425 CX-801 (IFN) initial safety for melanoma; Q126 CX-2051 update in advanced colorectal cancer"
X Link 2025-08-19T08:52Z [---] followers, [---] engagements

"Crinetics $CRNX Cash: $1.2B Net Loss Q2: $115.6M Runway: [----] Next: Sept [--] [----] PDUFA (paltusotine acromegaly)"
X Link 2025-08-19T08:52Z [---] followers, [---] engagements

"Monte Rosa $GLUE Cash: $295.5M Net Loss Q2: $12.3M Runway: [----] Next: Phase 1/2 of GSPT1-directed Molecular degrader MRT-2359 in prostate cancer additional results on track for H2 [----]. Phase [--] study of NEK7-directed molecular glue degrader (MGD) MRT-8102 underway to investigate a potential novel therapeutic approach for treating inflammatory diseases driven by the NLRP3 inflammasome; initial readout anticipated in H1 2026"
X Link 2025-08-19T08:52Z [---] followers, [--] engagements

"Ventyx $VTYX Cash: $209M Net Loss: $27M Runway: H226 Next: Q425 topline Ph2 data (VTX2735 recurrent pericarditis; VTX3232 cardio-metabolic)"
X Link 2025-08-19T08:52Z [---] followers, [---] engagements

"What scientific milestones are biotech companies expecting by the end of [----] And how could they impact their stock prices In #TaxiBiotech I review just a few examples 👉 Watch it here: #BiotechStocks #Investing #StockMarket #ClinicalTrials https://youtu.be/dRbRQGlcz4c https://youtu.be/dRbRQGlcz4c"
X Link 2025-08-31T09:50Z [---] followers, [---] engagements

"Novo Nordisk $NVO entra al combate 🥊 En el estudio real-world STEER (21.250 pacientes con obesidad + ECV sin diabetes): Wegovy (semaglutida [---] mg) 57% riesgo de infarto ictus o muerte vs tirzepatida. Eventos: 0.1% (15) con Wegovy vs 0.4% (39) con tirzepatida. ⚔ #Wegovy #Zepbound #Cardio"
X Link 2025-09-02T06:31Z [---] followers, [---] engagements

"Novo nordisk $NVO ready for battle 🥊 Real-world STEER study (21250 pts obesity + CVD no diabetes): Wegovy (semaglutide [---] mg) cut risk of heart attack stroke or death by 57% vs tirzepatide. Events: 0.1% (15) with Wegovy vs 0.4% (39) with tirzepatide. ⚔ #Wegovy #Zepbound #Cardio"
X Link 2025-09-02T06:32Z [---] followers, [---] engagements

"@Maximus_Holla $CRNX PDUFA on Sept [--]. Countdown begins . Lets see"
X Link 2025-09-02T19:44Z [---] followers, [---] engagements

"Another BIOTECH dives into crypto 💊➡💻 Propanc $PPCB plans to acquire $100M in Ethereum over [--] months to diversify assets Board: EthereumBitcoin: smart contracts Dapp efficiency If you want to copy @saylor copy him all the way: "There is no second best" https://www.globenewswire.com/news-release/2025/09/02/3142744/0/en/Propanc-Biopharma-Announces-Plan-to-Acquire-100-Million-of-Ethereum.html https://www.globenewswire.com/news-release/2025/09/02/3142744/0/en/Propanc-Biopharma-Announces-Plan-to-Acquire-100-Million-of-Ethereum.html"
X Link 2025-09-03T07:56Z [---] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing